Merck and Moderna Prepare FDA Filing for Personalized mRNA Melanoma Vaccine Paired with Keytruda After Phase 3 Results

Merck and Moderna are preparing to seek FDA approval for a personalized mRNA melanoma vaccine used with Keytruda. No filing date has been set.
This is a short summary. The full story is published by Medical Daily.
Read full story at Medical Daily